Multiple endocrine neoplasia type 2.

Area of Science:

• Endocrinology
• Genetics
• Oncology

Background:

• Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant disorder characterized by medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism.
• The syndrome arises from germline mutations in the RET proto-oncogene, with subtypes including MEN 2A, MEN 2B, and familial medullary thyroid carcinoma (FMTC).
• Current guidelines from the American Thyroid Association (2009) address clinical and genetic testing and treatment, but literature review reveals evolving perspectives.

Purpose of the Study:

• To review recent literature on Multiple Endocrine Neoplasia type 2 (MEN 2).
• To discuss future perspectives and challenges in managing MEN 2.
• To emphasize the need for specialized care and data collection for MEN 2 patients.

Main Methods:

• Literature review of recently published studies on MEN 2.
• Analysis of current recommendations and identification of areas for improvement.
• Discussion of clinical and genetic aspects, including rare DNA variants and double mutations.

Main Results:

• Critical handling of rare DNA variants and double mutations in RET proto-oncogene is necessary.
• Mutation-specific risk profiles and treatment recommendations are currently unavailable.
• There is a need for approved centers specializing in MEN 2 treatment for both adults and children.

Conclusions:

• Expertise in endoscopic adrenal-sparing surgery must be declared by surgeons.
• Mandatory registry-based follow-up is crucial for documenting outcomes and informing future patient counseling.
• Specialized centers and skilled surgeons are essential for optimal management of MEN 2 patients.